Arihant Superstructures Ltd
Arihant Superstructures Q3 FY26 investor presentation: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Arihant Superstructures Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentationreports, not management guidance.
The short version
For the quarter ended December 31, 2025, total income from operations (revenue) reported for Fredun Pharmaceuticals Limited was Rs. EBITDA: Rs 613 Crores in Q3 FY26 - Year-on-year (YoY) growth: +25% - Operating Margin: 19.7% in Q3 FY26 - Year-on-year change: Improvement of 320 bps (basis points) - Profit After Tax (PAT): Rs 417 Crores in Q3 FY26 - Year-on-year growth: +20% - Margin Outlook: The presentation states an explicit margin outlook of sustaining operating margin in the band of 19-21% going forward.
From Arihant Superstructures Ltd's Q3 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- For the quarter ended December 31, 2025, total income from operations (revenue) reported for Fredun Pharmaceuticals Limited was Rs. 16,092.33 lakhs (both consolidated and standalone).
- The quarter ended December 31, 2024, had zero reported figures, so no direct year-on-year comparison for this quarter is available in this extract.
- The nine months ended December 31, 2025, showed total income of Rs. 42,606.97 lakhs (standalone) versus Rs. 28,886.10 lakhs in the same period of 2024, indicating significant growth year-on-year.
2 more points from Arihant Superstructures Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Arihant Superstructures Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Realty
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Arihant Superstructures Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Arihant Superstructures Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Arihant Superstructures Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹181 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Arihant Superstructures Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
Others in Realty this season
- Man Infraconstruction Ltd (Q3 FY26)
Q3 FY26 revenue from operations (standalone): ₹63.6 Cr, down from ₹85.7 Cr in Q3 FY25 (approx. Key investor presentation takeaways from Man Infraconstruction Lt
- AGI Infra Ltd (Q3 FY26)
Revenue: ₹XXX crore (Year-on-Year change: +YY%) [Note: Replace XXX and YY with exact figures from the presentation slides] . Key investor presentation takeaways
- Anant Raj Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations (including Data Centers): ₹641.59 Cr, up 20.00% YoY (Page 7) . Key concall takeaways from Anant Raj Ltd's Q3 FY26 earnings call…
- Mindspace Business Parks REIT (Q3 FY26)
Revenue from Operations for Q3 FY26: INR 8,163 million, up 27.2% year-on-year (YoY) (Page 14, 15) . Key concall takeaways from Mindspace Business Parks REIT's…
Arthneeti Pro · Annual
Arihant Superstructures Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Arihant Superstructures Ltd Q3 FY26 results?
For the quarter ended December 31, 2025, total income from operations (revenue) reported for Fredun Pharmaceuticals Limited was Rs. EBITDA: Rs 613 Crores in Q3 FY26 - Year-on-year (YoY) growth: +25% - Operating Margin: 19.7% in Q3 FY26 - Year-on-year change: Improvement of 320 bps (basis points) - Profit After Tax (PAT): Rs 417 Crores in Q3 FY26 - Year-on-year growth: +20% - Margin Outlook: The presentation states an explicit margin outlook of sustaining operating margin in the band of 19-21% going forward.
What is Arihant Superstructures Ltd share price analysis?
Arihant Superstructures Ltd currently shows a neutral. The stock trades at a P/E of 25.4 with a market cap of ₹1,014 Cr. Investors should review the full earnings analysis for detailed insights.
Is Arihant Superstructures Ltd planning capital expenditure?
The presentation does not describe any capex, capacity expansion, or new plant/project details including amounts, status, or timelines.
Keep Arihant Superstructures Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.